OS Therapies Inc. Files S-1/A Amendment
Ticker: OSTX · Form: S-1/A · Filed: Jun 13, 2024 · CIK: 1795091
| Field | Detail |
|---|---|
| Company | Os Therapies Inc (OSTX) |
| Form Type | S-1/A |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $4.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceutical
TL;DR
OS Therapies Inc. filed an S-1/A amendment on 6/13/24. IPO/registration update.
AI Summary
OS Therapies Inc. filed an S-1/A amendment on June 13, 2024, for its registration statement (No. 333-279839). The company, incorporated in Delaware and based in Rockville, Maryland, operates in the Pharmaceutical Preparations sector (SIC 2834). This filing is an amendment to a previous registration, indicating ongoing efforts to go public or adjust existing registration details.
Why It Matters
This S-1/A filing is a step in the company's process towards a public offering or compliance with SEC regulations, providing updated information for potential investors.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to initial public offerings or significant corporate changes, which inherently carry market and execution risks.
Key Numbers
- 333-279839 — SEC File Number (Identifies the specific registration filing with the SEC.)
Key Players & Entities
- OS Therapies Inc. (company) — Registrant
- June 13, 2024 (date) — Filing Date
- 333-279839 (registration_number) — SEC Registration Number
- Delaware (jurisdiction) — State of Incorporation
- Rockville, Maryland (location) — Principal Executive Offices
- Paul A. Romness (person) — President and Chief Executive Officer
FAQ
What is the primary purpose of this S-1/A filing?
This is an amendment (Amendment No. 2) to a Form S-1 registration statement, indicating updates or changes to the company's initial filing for public offering or registration purposes.
When was this amendment filed with the SEC?
The amendment was filed on June 13, 2024.
What is OS Therapies Inc.'s principal business address?
The principal executive offices are located at 15825 Shady Grove Road, Suite 135, Rockville, Maryland 20850.
Who is the President and CEO of OS Therapies Inc. mentioned in the filing?
Paul A. Romness, MPH, is listed as the President and Chief Executive Officer.
In which state is OS Therapies Inc. incorporated?
OS Therapies Inc. is incorporated in Delaware.
Filing Stats: 4,605 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-06-13 14:05:34
Key Financial Figures
- $4.00 — s. The initial public offering price is $4.00 per share. We have applied to list our
Filing Documents
- ea0205761-08.htm (S-1/A) — 5927KB
- ea020576108ex4-2_osthera.htm (EX-4.2) — 74KB
- ea020576108ex23-1_osthera.htm (EX-23.1) — 4KB
- tos_logo.jpg (GRAPHIC) — 83KB
- timage_001.jpg (GRAPHIC) — 324KB
- timage_002.jpg (GRAPHIC) — 333KB
- tflowchart_001.jpg (GRAPHIC) — 317KB
- ex23-1_001.jpg (GRAPHIC) — 20KB
- ex23-1_002.jpg (GRAPHIC) — 66KB
- 0001213900-24-052373.txt ( ) — 17857KB
- osti-20240331.xsd (EX-101.SCH) — 71KB
- osti-20240331_cal.xml (EX-101.CAL) — 26KB
- osti-20240331_def.xml (EX-101.DEF) — 308KB
- osti-20240331_lab.xml (EX-101.LAB) — 462KB
- osti-20240331_pre.xml (EX-101.PRE) — 314KB
- ea0205761-08_htm.xml (XML) — 2850KB
RISK FACTORS
RISK FACTORS 14 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 50
USE OF PROCEEDS
USE OF PROCEEDS 51 DIVIDEND POLICY 53 CAPITALIZATION 54
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 57
BUSINESS
BUSINESS 69 MANAGEMENT 87
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 94
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 98 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 99
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 101 SHARES ELIGIBLE FOR FUTURE SALE 106
UNDERWRITING
UNDERWRITING 108 LEGAL MATTERS 112 EXPERTS 112 WHERE YOU CAN FIND MORE INFORMATION 112 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any applicable prospectus supplement. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriters are not, offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States. The industry and market data and certain other statistical information used throughout this prospectus are from our own research, surveys or studies conducted by third parties and indu